Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

161. Low molecular weight heparin effective for prevention of venous thromboembolism in patients with lower-leg immobilisation

Low molecular weight heparin effective for prevention of venous thromboembolism in patients with lower-leg immobilisation PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Low molecular weight heparin effective for prevention of venous thromboembolism in patients with lower-leg immobilisation Clinical question How effective is low molecular weight heparin (LMWH) for prevention of venous (...) thromboembolism (VTE) in patients with lower leg immobilisation? Bottom line LMWH significantly reduces VTE when immobilisation of the lower leg is required in outpatients. Further analysis showed a significant reduction in the occurrence of DVT when using LMWH in the following patient subgroups: surgical patients; non-surgical patients; patients with fractures; patients with soft-tissue injuries; patients with below-knee casts; a group with proximal thrombosis and a group with distal thrombosis. LMWH should

Cochrane PEARLS2009

162. Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction

Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute (...) Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial Welsh RC, Sauriol L, Zhang Z, Kolm P, Weintraub WS, Theroux P Record Status This is a critical

NHS Economic Evaluation Database.2009

163. Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy

Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Tillman J CRD summary The author concluded that regional citrate anticoagulation was associated with increased haemofilter circuit survival (...) time and lower risk of bleeding, compared with systemic heparin anticoagulation in continuous renal replacement therapy for patients with acute renal failure. The reliability of this conclusion is unclear, given restrictions in the search strategy, and failure to minimise errors and bias in the review process. Authors' objectives To compare systemic heparin and regional citrate anticoagulation in continuous renal replacement therapy for patients with acute renal failure. Searching The Cochrane

DARE.2009

164. Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials

Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials (...) Singh S, Bahekar A, Molnar J, Khosla S, Arora R CRD summary The review evaluated low-molecular weight heparins versus unfractionated heparin, in addition to fibrinolytic therapy, in patients with acute ST-segment elevation myocardial infarction. Low-molecular weight heparins significantly reduced reinfarction, but increased major bleeding risk compared with unfractionated heparin. The reliability of the authors’ conclusions is unclear given limitations in reporting, particularly of the review

DARE.2009

165. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials

Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term (...) treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials Louzada ML, Majeed H, Wells PS CRD summary This review assessed the efficacy of low molecular weight heparin compared to Vitamin K antagonists for long-term treatment of cancer-associated venous thromboembolism in adults and found that low molecular weight heparin was the superior treatment. Based on the evidence, the authors' conclusions and recommendation for further research appeared

DARE.2009

166. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review

Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review Ribic C, Lim W, Cook D, Crowther M CRD summary The authors concluded that low molecular weight heparin could not be recommended routinely and that further (...) trials were required to test patient-specific endpoints. The authors' conclusions were appropriate for the evidence presented. Authors' objectives To assess the effect of low molecular weight heparin thromboprophylaxis in medical-surgical critically ill patients in the intensive care unit. Searching MEDLINE was searched from 1950 to February 2008 for English-language articles. Reference lists of retrieved articles were examined and content experts were consulted to identify additional material. Study

DARE.2009

167. Heparin-bonded polytetrafluoroethylene (PTFE) gore propaten vascular graft (W.L. Gore & Associates Inc.) for treatment of peripheral arterial disease

Heparin-bonded polytetrafluoroethylene (PTFE) gore propaten vascular graft (W.L. Gore & Associates Inc.) for treatment of peripheral arterial disease Heparin-bonded polytetrafluoroethylene (PTFE) gore propaten vascular graft (W.L. Gore & Associates Inc.) for treatment of peripheral arterial disease Heparin-bonded polytetrafluoroethylene (PTFE) gore propaten vascular graft (W.L. Gore & Associates Inc.) for treatment of peripheral arterial disease Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from Citation Heparin-bonded polytetrafluoroethylene (PTFE) gore propaten vascular graft (W.L. Gore & Associates Inc.) for treatment of peripheral arterial disease . Lansdale: HAYES, Inc.. 2009 Authors' objectives According to the American Heart Association, 8 to 12 million Americans have peripheral arterial disease (PAD), a disease in which blood flow

Health Technology Assessment (HTA) Database.2009

168. Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty

Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty 18534421 2008 11 12 2009 02 27 2016 11 24 1532-8406 23 8 2008 Dec The Journal of arthroplasty J Arthroplasty Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty. 1122-7 10.1016/j.arth.2007.11.006 This preliminary prospective study (...) to determine the rate of deep venous thrombosis (DVT) examined 277 patients undergoing total knee or total hip arthroplasty (TKA or THA) who were randomized to use a portable, continuous enhanced circulation therapy (CECT) compression device and low-molecular-weight heparin (LMWH) or to receive LMWH alone. Patients were screened for DVT using duplex ultrasound at hospital discharge and followed clinically for 3 months. In TKA, 5 DVTs (6.6%) occurred in the CECT + LMWH group compared with one pulmonary

EvidenceUpdates2009

169. Outbreak of Adverse Reactions Associated with Contaminated Heparin.

Outbreak of Adverse Reactions Associated with Contaminated Heparin. BACKGROUND: In January 2008, the Centers for Disease Control and Prevention began a nationwide investigation of severe adverse reactions that were first detected in a single hemodialysis facility. Preliminary findings suggested that heparin was a possible cause of the reactions. METHODS: Information on clinical manifestations and on exposure was collected for patients who had signs and symptoms that were consistent (...) with an allergic-type reaction after November 1, 2007. Twenty-one dialysis facilities that reported reactions and 23 facilities that reported no reactions were included in a case-control study to identify facility-level risk factors. Unopened heparin vials from facilities that reported reactions were tested for contaminants. RESULTS: A total of 152 adverse reactions associated with heparin were identified in 113 patients from 13 states from November 19, 2007, through January 31, 2008. The use of heparin

NEJM2008 Full Text: Link to full Text with Trip Pro

170. Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes

Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes 19022155 2008 11 21 2008 12 23 2016 11 24 1558-3597 52 22 2008 Nov 25 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early (...) incorporating glycoprotein IIb/IIIa receptor inhibitors (GPI) for moderate- and high-risk NSTE-ACS. In ACUITY, 7,851 U.S. patients were randomized to: 1) heparin (unfractionated or enoxaparin) + GPI; 2) bivalirudin + GPI; or 3) bivalirudin monotherapy. Patients assigned to GPI were also randomized to upstream GPI before catheterization or selective GPI only with percutaneous coronary intervention. Resource use data were collected prospectively through 30-day follow-up. Costs were estimated with standard

EvidenceUpdates2008

171. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial

Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial 18519426 2008 08 04 2008 12 24 2014 11 20 1522-9645 29 15 2008 Aug European heart journal Eur. Heart J. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. 1827-33 10.1093/eurheartj/ehn236 Elderly patients are at high risk from non-ST-segment elevation acute (...) coronary syndromes (NSTE ACS) as well as from treatment-related complications. Age-associated changes in physiology may alter the risk and benefit expected from therapy. The SYNERGY database was used to study the influence of age on treatment outcomes with enoxaparin vs. unfractionated heparin (UFH) in patients with high-risk NSTE ACS. Age was analysed as a continuous and categorical variable (<65, 65-74, and >or=75 years, and <75 and >or=75 years) for descriptive purposes. Logistic regression was used

EvidenceUpdates2008

172. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. BACKGROUND: Low-molecular-weight heparins and heparinoids are anticoagulants that may be associated with lower risks of haemorrhage and more powerful antithrombotic effects than standard unfractionated heparin. This is an updated version of the original Cochrane review first published in Issue 1, 1995 and previously updated in Issue 2, 2005. OBJECTIVES: To compare the effects (...) of low-molecular-weight heparins or heparinoids with those of unfractionated heparin in people with acute, confirmed or presumed, ischaemic stroke. SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (last searched June 2007). In addition we searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2007), MEDLINE (1966 to June 2007) and EMBASE (1980 to June 2007). For previous versions of this review we searched MedStrategy (1995) and also contacted pharmaceutical companies

Cochrane2008

173. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis

Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis 18574082 2008 06 24 2008 07 08 2008 12 17 1538-3679 168 12 2008 Jun 23 Archives of internal medicine Arch. Intern. Med. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. 1261-9 10.1001/archinte.168.12.1261 The relative benefits and harms (...) of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) are required for judgments regarding the appropriate perioperative thromboprophylaxis in patients with cancer. We systematically reviewed the literature to quantify these effects. The comprehensive searches included (1) an electronic search of MEDLINE, EMBASE, ISI the Web of Science, and CENTRAL (The Cochrane Central Register of Controlled Trials); (2) a hand search of relevant conference proceedings; (3) a reference check of included trials; and (4) use

EvidenceUpdates2008

174. Annals of Internal Medicine Article Low-Molecular-Weight Heparin versus Compression Stockings for Thromboprophylaxis after Knee Arthroscopy

Annals of Internal Medicine Article Low-Molecular-Weight Heparin versus Compression Stockings for Thromboprophylaxis after Knee Arthroscopy Annals of Internal Medicine Artic... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2008 ) Volume: 149 , Issue: 2 , Publisher: Am Coll Physicians , Pages: 73-82 ISSN: 00034819 PubMed: Available from or Find this paper at: Abstract BACKGROUND: Knee (...) arthroscopy, the most common orthopedic operation worldwide, carries a definite risk for deep venous thrombosis; however, postsurgical thromboprophylaxis is not routinely recommended. OBJECTIVE: To evaluate whether low-molecular-weight heparin (LMWH) better prevents deep venous thrombosis and does not cause more complications than graduated compression stockings in adults having knee arthroscopy. DESIGN: Assessor-blind, randomized, controlled trial. SETTING: The Department of Knee Surgery, Abano Terme

Annals of Internal Medicine2008

175. Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease

Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease BestBets: Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease Report By: Andrew Munro - Staff Specialist Search checked by Cain English - Emergency Registrar Institution: Coffs Harbour Base Hospital Date (...) Submitted: 4th September 2007 Date Completed: 8th May 2008 Last Modified: 5th November 2007 Status: Green (complete) Three Part Question In [patients with DVT] is [subcutaneous unfractionated heparin as efficacious as low-molecular-weight heparin] in the [prevention of thrombo-embolic sequelae]? Clinical Scenario An Emergency Department Registrar presented a paper at our journal club showing the efficaciousness and cost effectiveness of home treatment with unfractionated heparin (UFH) in comparison

BestBETS2008

176. Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System.

Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System. BACKGROUND: There is an urgent need to determine whether oversulfated chondroitin sulfate (OSCS), a compound contaminating heparin supplies worldwide, is the cause of the severe anaphylactoid reactions that have occurred after intravenous heparin administration in the United States and Germany. METHODS: Heparin procured from the Food and Drug Administration, consisting of suspect lots of heparin (...) associated with the clinical events as well as control lots of heparin, were screened in a blinded fashion both for the presence of OSCS and for any biologic activity that could potentially link the contaminant to the observed clinical adverse events. In vitro assays for the activation of the contact system and the complement cascade were performed. In addition, the ability of OSCS to recapitulate key clinical manifestations in vivo was tested in swine. RESULTS: The OSCS found in contaminated lots

NEJM2008 Full Text: Link to full Text with Trip Pro

177. Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters.

Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. BACKGROUND: Complications associated with peripherally placed percutaneous central venous catheters (PCVC) in neonates include mechanical complications (catheter thrombosis, occlusion or dislodgement) and infection. Strategies to prevent catheter thrombosis and occlusion include the use of heparin. However, heparin is known to be associated (...) with complications such as bleeding and thrombocytopenia. OBJECTIVES: PRIMARY OBJECTIVE: To assess the effectiveness of heparin for prevention of catheter related thrombosis. SECONDARY OBJECTIVES: To assess the effectiveness of heparin on catheter occlusion, duration of catheter patency, catheter related sepsis and complications associated with the use of heparin. SEARCH STRATEGY: A literature search of MEDLINE, EMBASE, CINAHL from their inception to December 2007, The Cochrane Library (Issue 4, 2007

Cochrane2008

178. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.

Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. BACKGROUND: There are a limited number of treatment options for patients with ulcerative colitis (UC). An increased risk of thrombosis in UC coupled with an observation that UC patients being treated with anticoagulant therapy for thrombotic events had an improvement in their bowel symptoms led to trials examining the use of unfractionated heparin (UFH) and low molecular weight heparins (LMWH) in (...) patients with active UC. OBJECTIVES: To review randomized trials examining the efficacy of unfractionated heparin (UFH) or low molecular weight heparins (LMWH) for remission induction in patients with ulcerative colitis. SEARCH STRATEGY: The MEDLINE (PUBMED), and EMBASE databases, The Cochrane Central Register of Controlled Trials, the Cochrane IBD/FBD group specialized trials register, review papers on ulcerative colitis, and references from identified papers were searched in an effort to identify all

Cochrane2008

179. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis

Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis Shorr A F, Jackson W L, Sherner J H, Moores L K CRD (...) summary This review found that low molecular weight heparins are associated with reduced risk of venous thromboembolism following ischaemic stroke, and no increased risk of bleeding compared with unfractionated heparin use. Overall this was a well-conducted review and the results appear to be reliable. Authors' objectives To compare low molecular weight heparin (LMWH) with unfractionated heparin (UFH) for the prevention of venous thromboembolism (VTE) following ischaemic cerebrovascular accidents (CVA

DARE.2008

180. Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity

Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Bramham K, Varrier M, Asgari E, Makanjuola D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the costs and outcomes associated with the use of unfractionated heparin (UFH) and a low-molecular-weight heparin (LMWH, Tinzaparin TM ) for anticoagulation in patients on haemodialysis. The authors concluded

NHS Economic Evaluation Database.2008